FDA Grants Orphan Drug Designation to AND017 for the Treatment of Sickle Cell Disease

The FDA granted an orphan drug designation to AND017 for the treatment of sickle cell disease (SCD). The preclinical work that supports the ODD for AND017 in SCD will be presented in future scientific meetings and published in journals, according to experts.